Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment by Russo, D et al.
OPEN
ORIGINAL ARTICLE
Managing chronic myeloid leukaemia in the elderly with
intermittent imatinib treatment
D Russo1, M Malagola1, C Skert1, V Cancelli1, D Turri2, P Pregno3, M Bergamaschi4, M Fogli5, N Testoni5, A De Vivo5, F Castagnetti5,
E Pungolino6, F Stagno7, M Breccia8, B Martino9, T Intermesoli10, GR Cambrin11, G Nicolini12, E Abruzzese13, M Tiribelli14, C Bigazzi15,
E Usala16, S Russo17, A Russo-Rossi18, M Lunghi19, M Bocchia20, A D’Emilio21, V Santini22, M Girasoli23, R Di Lorenzo24, S Bernardi1,
A Di Palma1, BM Cesana25, S Soverini5, G Martinelli5, G Rosti5 and M Baccarani26
The aim of this study was to investigate the effects of a non-standard, intermittent imatinib treatment in elderly patients with
Philadelphia-positive chronic myeloid leukaemia and to answer the question on which dose should be used once a stable optimal
response has been achieved. Seventy-six patients aged ⩾ 65 years in optimal and stable response with ⩾ 2 years of standard
imatinib treatment were enrolled in a study testing a regimen of intermittent imatinib (INTERIM; 1-month on and 1-month off). With
a minimum follow-up of 6 years, 16/76 patients (21%) have lost complete cytogenetic response (CCyR) and major molecular
response (MMR), and 16 patients (21%) have lost MMR only. All these patients were given imatinib again, the same dose, on the
standard schedule and achieved again CCyR and MMR or an even deeper molecular response. The probability of remaining on
INTERIM at 6 years was 48% (95% conﬁdence interval 35–59%). Nine patients died in remission. No progressions were recorded.
Side effects of continuous treatment were reduced by 50%. In optimal and stable responders, a policy of intermittent imatinib
treatment is feasible, is successful in about 50% of patients and is safe, as all the patients who relapsed could be brought back to
optimal response.
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INTRODUCTION
More than 80% of patients with Philadelphia-positive (Ph+), BCR-
ABL1+, chronic phase chronic myeloid leukaemia (CML) are alive
after 45 years and are projected to have a life expectancy very
close or even identical to that of a non-leukaemic matched control
population.1–5 These results were obtained using the tyrosine
kinase inhibitor (TKI) imatinib (Gleevec or Glivec, Novartis
Pharmaceutics), frontline.1–9 Some of these patients, in a propor-
tion estimated to range between 20% and 40%, achieve a deep
molecular response (DMR), that is to say a BCR-ABL1 transcripts
level ⩽ 0.01% on the International Scale.9–12 About 50% of them
were reported to maintain that remission status after discontinua-
tion of imatinib and to achieve a stable treatment-free remission
(TFR).13–16 The introduction of the so-called second-generation
TKIs, both in ﬁrst and second line, is expected to fare even better,
with up to 50% or more of the patients achieving a DMR,17–20 and
up to ⩾ 50% of them entering into a TFR status. If these
expectations will be fulﬁlled, the proportion of patients who will
be in TFR will range between 25% and 50%. However, about
⩾ 50% of all patients will not be able to discontinue, and for them,
the current policy is to continue the treatment with the same TKI,
at the same dose and schedule, indeﬁnitely and lifelong.3,5 Until
today, the case of the chronic treatment of these patients has not
received the same attention as the case of TFR policies. But the
issue is important for obvious reasons of quality of life,21
treatment-related side effects and complications22–29 and also
because of drug and management costs.3,5,30
For these reasons, we designed and initiated a pilot study
testing the effect of a non-standard, dose-reduced, policy of
imatinib treatment.31 We report here on the long-term results of
that trial.
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ClinicalTrials.Gov with the number: NCT00858806) was limited to patients
aged ⩾ 65 years who had been treated ﬁrst line with imatinib once daily
(OD) for chronic phase CML, for a minimum of 2 years, and were in
complete cytogenetic response (CCyR). One hundred and fourteen
patients were screened in 24 GIMEMA (Gruppo Italiano Malattie
Ematologiche dell’Adulto) centres. Nineteen patients (17%) did not ﬁt
the inclusion criteria, 19 (17%) did not consent and 76 were enrolled. The
median age at enrolment was 72 years (range 65–83 years). The median
duration of imatinib treatment was 5.75 years (range 2.0–6.6 years). Sokal
risk32 distribution at diagnosis was 33% low risk, 55% intermediate risk and
12% high risk. At enrolment, all patients were in CCyR, and all but one were
in major molecular response (MMR or MR3.0, BCR-ABL1 transcripts level
⩽ 0.1% on the International Scale).
The daily dose of imatinib was not modiﬁed (400mg OD in 81% of
patients, 200–300mg OD in 17% of patients and 600mg in one patient),
but imatinib was given 1 week on/1 week off for 1 month, 2 weeks
on/2 weeks off for another 2 months and then on a 1 month on/1 month
off schedule. The protocol originally mandated to proceed with the
intermittent schedule as long as the CCyR was maintained so that the
return to continuous daily treatment was mandatory only in case of CCyR
loss. After 2 years, an amendment allowed a return to the continuous daily
schedule also in case of MMR loss.
The cytogenetic response was assessed by chromosome banding
analysis of marrow cell metaphases or by interphase ﬂuorescence in situ
hybridization analysis of peripheral blood cell nuclei, as described
elsewhere.33 The cytogenetic test was performed every 6 months for the
ﬁrst 2 years, and then only in case of loss of MR3.0. A CCyR was deﬁned
either by the absence of Ph+ metaphases out of at least 20 metaphases or
by o1% BCR-ABL1+ nuclei out of 4200 nuclei. The molecular response
was evaluated every 3 months and was reported according to the
International Scale by reverse transcriptase-PCR of peripheral blood
leukocytes.34–36 The tests were performed at one GIMEMA reference
laboratory for 4 years, then also at other laboratories that had received
their conversion factor through the EUTOS project36 and were certiﬁed by
the Labnet GIMEMA network. A mutational analysis, by Sanger sequencing
technique,37 was performed in the Bologna reference laboratory in all
cases of loss of CCyR or MR3.0. The deﬁnition of the phases of the disease
and of response was those recommended by EuropeanLeukemiaNet
2013.3
BASELINE
76 pts on INTERIM
16 pts lost 
CCgR and MR3.0
@ 72 MONTHS
30 pts on INTERIM
16 pts resumed 
IM daily
1 pt regained CCgR 
13 pts regained CCgR and MR3.0
1 pt regained CCgR and MR4.0
1 pt lost at f up
16 pts lost 
MR3.0 alone 
16  pts resumed 
IM daily
1 pt maintained CCgR
12 pts regained MR3.0
2 pts regained MR4.0
1 pt regained MR4.5
9 pts died
@ 24th mo myocardial infarction CCgR and MR3.0 OFF NTERIM
@ 36th mo intracranial hemorrahage CCgr and MR3.0 ON NTERIM
@ 37th mo carcinosis CCgR and MR3.0 ON NTERIM
@ 37th mo COPD CCgR and MR3.0 ON NTERIM
@ 40th mo pancreas neoplasia CCgR and MR3.0 ON NTERIM
@ 40th mo COPD CCgR and MR3.0 OFF NTERIM
@ 60th mo kidney neoplasia CCgR and MR3.0 ON NTERIM
@ 63rd mo lung neoplasia CCgR and MR3.0 ON NTERIM
@ 65th mo lung neoplasia CCgR and MR3.0 OFF NTERIM
@ 15th mo discontinued INTERIM atrial fibrillation CCgR and MR3.0
@ 24th mo discontinued INTERIM informed consent withdrawn CCgR and MR3.0
@ 59th mo discontinued INTERIM informed consent withdrawn CCgR
@ 60th mo discontinued INTERIM informed consent withdrawn Unknown
@ 70th mo discontinued INTERIM informed consent withdrawn CCgR and MR4.0
Figure 1. Flow diagram of INTERIM study—update at 72 months.
Intermittent imatinib treatment of CML
D Russo et al
2
Blood Cancer Journal
Statistics
The Kaplan–Meier method38 was used to estimate overall survival. Death
by any cause was the event of interest for overall survival. CCgR loss (CBA-
positivity), MMR (MR3.0) loss and the probability of continuing INTERIM
were calculated using the cumulative incidence procedure.39 Death was
considered competing risk for CCgR and MMR loss, whereas death and
refusal were the competing risks for the probability of continuing INTERIM.
RESULTS
The results of intermittent imatinib treatment, with a median
follow-up of 5.75 years (range 2.0–6.6 years) are shown in the ﬂow
diagram (Figure 1). Sixteen patients (21%) lost CCyR and MR3.0, 11
of them during the ﬁrst 2 years and 5 later on. One of these
patients was lost to follow-up. All the remaining 15 patients
recovered a CCyR, with MR3.0 in 13 patients and MR4.0 in one.
Sixteen patients (21%) lost MR3.0 after the second year. All these
patients recovered an MR3.0, and two of them achieved a DMR
(MR4.0 in one case and MR4.5 in one case). One patient went off the
study because of an atrial ﬁbrillation. He was back on standard
imatinib, then was switched to nilotinib and is in MMR. Four
patients withdrew their consent after 24–70 months. They went
back to standard daily imatinib; 3 are in MR3.0, the fourth achieved
a MR4.0 and is currently in TFR. Nine patients (12%) died after
24–60 months, being in MR3.0, of the causes that are listed in the
ﬂow diagram, namely another cancer (ﬁve patients), chronic
pulmonary obstructive disease (two patients) and cardiovascular
events (two patients). The median age at death was 75 years
(range 72–80). No patients progressed to accelerated phase or
blastic phase. No BCR-ABL1 kinase domain point mutations were
detected at the time of CCyR or MR3.0 loss.
The distribution over time of the loss of CCyR and of MR3.0 is
shown in Figures 2a and b, respectively. The probability of
maintaining the intermittent treatment schedule is shown in
Figure 3a, where events were the return to the continuous, daily
treatment, whatever the reason for that. At 6 years, 48% of
patients were still on the intermittent schedule. Overall survival is
shown in Figure 3b, where it should be noticed that all deaths
occurred in remission. There were no progressions.
With a median follow-up of about 6 years, 30 patients are still
on intermittent treatment taking the same imatinib dose as at
baseline, 1 month on/1 month off. Four of them are in CCyR, 4 are
in MR3.0, 20 are in MR4.0 and 2 are in MR4.5.
DISCUSSION
The current policies of TKI treatment of chronic phase CML
mandate using TKIs at their respective approved or maximum
tolerated doses lifelong, with the possibility of opening a window
for treatment discontinuation when a DMR has been achieved and
maintained for an as yet unspeciﬁed period of time.3,5,12,16,40 The
window for treatment discontinuation can be enlarged in some of
the patients who received imatinib ﬁrst line, by switching early or
late to a second-generation TKI,40–43 as well as using second-
generation TKIs ﬁrst line.17–20,44,45 Other policies have not been
tested prospectively, particularly for treatments alternative to
discontinuation, when discontinuation is not possible. The
importance of the compliance to the treatment dose is high-
lighted by studies reporting that poor compliance is associated
with a poorer molecular response.46,47 However, it is time to open
a debate not on compliance but on which dose should be used for
chronic treatment, once a stable, optimal response has been
achieved.
The concept of dose adaptation for chronic treatment can be
tested in many different ways. Different schedules, such as a
continuous daily treatment with a reduced dose or 1 day on/1 day
off or 1 week on/1 week off, could be tested. In this exploratory
study, it was decided to maintain the standard daily dose on a
1 month on/1 month off schedule. No pharmacokinetic studies
were performed, but it is conceivable that the plasma concentra-
tion of imatinib fell to zero during the month off.
This study shows that a policy of imatinib reduction to 50% of
the initial standard dose was associated with a substantial loss of
response in 42% of patients but had no negative effects on
outcome, particularly on progression and leukaemia-related
deaths. It should be noted that at baseline all patients were in
MMR, while after 6 years of intermittent treatment 22 of the
original 76 patients (29%) were in DMR and could be eligible for a
trial of treatment discontinuation. Therefore, even an intermittent
schedule can improve the response, with time. A systematic,
prospective study of the quality of life was not designed and
performed. All these patients were tolerating imatinib well. Only
20 of them were complaining of minor side effects. In all, 50% of
them reported the disappearance of the side effects, particularly
of muscle pain and cramps, and of ﬂuid retention. No evidence of
a ‘discontinuation syndrome’ was found, as it was reported in
patients discontinuing imatinib in the EUROSKI study.48,49 In this
exploratory study, only elderly patients (⩾65 years) were selected
and enrolled, because elderly patients tolerate TKIs less well, have
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Figure 2. (a) Probability of maintaining the CCyR. In all, 16/76
patients (21%) lost CCyR, of whom 11 during the ﬁrst 2 years and 5
later on. The probability of remaining in CCyR was 84% (95% CI
73–90) at 2 years, 81% (95% CI 69–88) at 4 years and 76% (95% CI
64–84) at 6 years. All 16 patients but 1 who was lost to follow-up
were back to continuous imatinib treatment, same daily dose, and
recovered the CCyR. (b) Probability of maintaining the MMR. In all,
32/76 patients (42%) lost MMR, including the 16 patients who had
lost also the CCyR (Figure 1). The probability of remaining in MMR
was 67% (95% CI 54–76) at 2 years and 60% (95% CI 47–70) at 4 and
6 years. All 32 patients but 1 who was lost to follow-up were back to
continuous imatinib treatment, same daily dose, and recovered
the MMR.
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more comorbidities, take more medications and have a shorter life
expectancy. Moreover, the median age at diagnosis is already
close to 60 years,50 and the proportion of elderly patients is
destined to grow with time. However, also the younger patients
who will not achieve a TFR will deserve attention. Although there
is only another study (DESTINY study—ClinicalTrials.gov
NCT01804985) looking for the minimum effective dose of any
TKI, there is no doubt that the so called standard or approved
dose is critical for achieving an optimal response as fast as
possible and to prevent progression to blastic phase.3,5 However,
the issue is not to challenge the choice of the initial dose but to
understand if the same dose is required indeﬁnitely, and if so, for
which purpose. This challenge has biological, clinical and ﬁnancial
implications. Biologically, almost all studies suggest that once an
optimal response is achieved, the residual Ph+ cells may not be
completely BCR-ABL1 addicted, and are resistant to TKI
inhibition,51,52 so that it may be necessary to consider other
approaches testing other drugs in trials where toxicity and safety
may prevail.53 In any case, those residual Ph+ cells can hardly give
rise to new resistant Ph+ clones, because late relapses are
exceptional.9 Therefore, the probability of dying of leukaemia
becomes so small that one must worry more of other diseases and
of the risk of treatment-related complications, a risk that will never
be equal to zero, and that is difﬁcult to predict over a very long
period of time.3,5,22–24 From a ﬁnancial perspective, the indeﬁnite
continuation of the standard, approved dose will expand the cost
of the treatment exponentially.30 These considerations are also a
valid argument in favour of a policy of treatment discontinuation
and TFR, a policy that is more radical and more appealing.11,12,16
However, the point is not only which policy is ‘better’. The point is
to acknowledge that a policy of TFR cannot be always successful,
because at least 50% of patients are estimated to never reach a
TFR, even with the largest use of second-generation TKIs. For the
patients who do not achieve a TFR, it is necessary to reconsider
some current concepts of treatment and to begin to look for a
‘minimum effective therapy’.
On these bases, we continue to work on the intermittent
schedule with a standard daily dose, and we are now testing a
progressive increase of the off-treatment period, up to 1 month
on/3 months off.
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